News
-
According to Satsuma Pharmaceuticals, the FDA has approved the company’s NDA for Atzumi dihydroergotamine nasal powder (STS101) for the treatment of migraine in adults. Although the Phase 3 SUMMIT trial of STS101 failed to meet its… Read more . . .
-
Inhalation CDMO Bespak announced that it has completed an independently verified life cycle assessment to evaluate environmental impacts associated with materials and manufacturing of its BK357 metered dose inhaler valve. The company said that the assessment… Read more . . .
-
Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical… Read more . . .
-
Akita Biosciences announced that a grant from Flu Lab will fund a pilot study of the company’s Profi prophylactic nasal spray in healthcare workers. Akita launched Profi, an OTC gel-forming drug-free nasal spray, in 2023… Read more . . .
-
Swedish DPI developer Iconovo has announced that it will lay off about 10 employees as it switches its focus to commercialization of its existing dry powder inhalation platforms, including the ICOres reservoir-based DPI, the ICOpre… Read more . . .
-
Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company’s lead candidate, LTI-03. Both of the new… Read more . . .
-
CDMO Kindeva has announced the appointment of Melanie Cerullo as Chief Quality Officer. Cerullo was most recently Chief Quality and Regulatory Officer at Recipharm’s ReciBioPharm business unit and previously served in quality roles at Wave Life… Read more . . .
-
AptarGroup announced that its subsidiary Nanopharm is initiating a clinical study to validate the SmartTrack in-vitro-in-silico modeling platform as an alternative to clinical endpoint studies for determining bioequivalence of inhaled drug products. The study will… Read more . . .
-
Neurelis announced that the FDA has approved the use of Valtoco diazepam nasal spray for the treatment of seizure clusters in children aged 2 years of age and older. The FDA approved Valtoco for use in… Read more . . .
-
Aurobindo has reported to the National Stock Exchange of India that the FDA issued a Form 483 on April 11, 2025, one day after the agency completed an inspection of a manufacturing facility in North… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan